Compare Novavax Inc (NVAX) vs ON Holding AG (ONON) Price & Performance

Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.

The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.

ONON trades at $27.27, down 2.57% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 64.82% gross margin and 12.3% net income margin, while analyst consensus remains optimistic with a $45.67 price target. Recent news highlights robust APAC growth but notes tariff and cost risks.

Outlook is mixed: strong DTC growth and margin expansion support upside, but near-term headwinds include U.S. tariffs and wholesale restraint. The stock's current valuation near support levels may offer entry points for long-term investors despite technical weakness.